I am thrilled to have Inflexion on board as a partner. Their track record in backing high-growth businesses combined with their life sciences experience gives me great conviction that they are well placed to support Proteros in its further growth trajectory.

Dr Torsten Neuefeind Founder and CEO, Proteros

About 

Inflexion Partnership Capital is backing founder-led Proteros Biostructures, a market-leading drug discovery platform, through its next phase of international growth.

Proteros is a leading Munich-based contract research organisation specialising in structural biology. Its cutting-edge platform enables users to map the shape of a drug target with a high degree of precision as it supports over 200 pharma and biotech partners in the US, Europe and Japan to reach the right results and accelerate their overall research timelines, helping them to lead optimisation and clinical programmes.

Value acceleration 

Inflexion is supporting Proteros to scale globally, both organically and through acquisition, particularly in the US. Inflexion’s expertise in healthcare, M&A and commercial strategy is strengthening Proteros’ overall value proposition for its blue-chip customer base, supporting with M&A strategy & opportunities and refining its finance and marketing approach.  

I am thrilled to have Inflexion on board as a partner. Their track record in backing high-growth businesses combined with their life sciences experience gives me great conviction that they are well placed to support Proteros in its further growth trajectory.

Dr Torsten Neuefeind Founder and CEO, Proteros